Compare · AZN vs SAVA
AZN vs SAVA
Side-by-side comparison of AstraZeneca PLC (AZN) and Cassava Sciences Inc. (SAVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and SAVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $266.82B, about 167.7x SAVA ($1.59B).
- Over the past year, AZN is up 105.1% and SAVA is down 33.7% - AZN leads by 138.8 points.
- AZN has hit the wire 18 times in the past 4 weeks while SAVA has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 9 for SAVA).
- Company
- AstraZeneca PLC
- Cassava Sciences Inc.
- Price
- $169.48-0.36%
- $2.38+12.80%
- Market cap
- $266.82B
- $1.59B
- 1M return
- +3.14%
- +16.95%
- 1Y return
- +105.05%
- -33.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 9
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Cassava Sciences Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Latest AZN
- AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
- SEC Form 6-K filed by AstraZeneca PLC
- Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- Gabelli To Host 8th Annual Healthcare Symposium
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
Latest SAVA
- SEC Form 10-K filed by Cassava Sciences Inc.
- Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cassava Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
- Cassava Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Cassava Announces Closure of U.S. Department of Justice Investigation
- Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease
- Cassava Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form 8-K/A filed by Cassava Sciences Inc.
- Cassava Sciences Inc. filed SEC Form 8-K: Other Events